Better Therapeutics- Tradeable Rights - March 2021 Current Cash

The latest current cash for MCADR is $6.6M as of September 2023. That compares with $22M in the prior-year period — down 70.4% year over year. Investors often review this figure alongside Better Therapeutics- Tradeable Rights - March 2021's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCADR's current cash moved from $22M to $6.6M — a 70.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics- Tradeable Rights - March 2021's operating scale or balance-sheet position.

A current cash figure of $6.6M for MCADR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MCADR's current cash ($6.6M), review year-over-year change from $22M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.